{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T00:49:06Z","timestamp":1793148546182,"version":"4.5.0"},"reference-count":37,"publisher":"BMJ","issue":"10","license":[{"start":{"date-parts":[[2025,5,19]],"date-time":"2025-05-19T00:00:00Z","timestamp":1747612800000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100006041","name":"Innovate UK","doi-asserted-by":"publisher","award":["2811328"],"award-info":[{"award-number":["2811328"]}],"id":[{"id":"10.13039\/501100006041","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000272","name":"National Institute for Health and Care Research","doi-asserted-by":"publisher","award":["No award\/grant number."],"award-info":[{"award-number":["No award\/grant number."]}],"id":[{"id":"10.13039\/501100000272","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["Thorax"],"accepted":{"date-parts":[[2025,4,9]]},"published-print":{"date-parts":[[2025,10]]},"abstract":"<jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>Infliximab, an anti-TNF agent, is used to treat sarcoidosis that does not respond to corticosteroids or second-line agents. The efficacy of other anti-TNF agents, non-TNF biologics and targeted synthetic therapies remains unclear. This study aims to evaluate the role of these therapies in the management of multisystem sarcoidosis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      We conducted a systematic literature search to identify trials of biological and targeted synthetic therapies in sarcoidosis. Meta-analyses examined %-predicted forced vital capacity (FVC), as mean change from baseline. Heterogeneity was measured using the I\n                      <jats:sup>2<\/jats:sup>\n                      statistic. Vote counting based on the direction of effect, as recommended by the Cochrane network, was used to synthesise study estimates.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>The search identified 6777 records. Sixteen studies met the inclusion criteria. These included 8 randomised control trials (RCTs) and 8 single-arm trials. Fourteen studies evaluated biologic therapies: infliximab (n=5), adalimumab (n=2), etanercept (n=2), golimumab (n=1), rituximab (n=1), anakinra (n=1), sarilumab (n=1), ustekinumab (n=1) and efzofitimod (n=1). Two trials assessed the targeted synthetic therapy tofacitinib. Risk of bias was high in five of eight RCTs. Meta-analysis of %-predicted FVC showed modest improvement with treatment (mean change: 4.79% (95% CI 1.22 to 8.35), driven by anti-TNF trials 5.70% (95% CI 1.61 to 9.78). Heterogeneity was substantial (I\u00b2=76.3%). In data synthesis using vote counting, infliximab, adalimumab, efzofitimod and tofacitinib demonstrated a positive direction of effect across all estimates, though improvements in several outcomes did not reach thresholds for minimal clinically important differences.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Meta-analysis supports infliximab use in pulmonary sarcoidosis, although improvements in lung function are modest. There is limited but promising evidence for the use of adalimumab and tofacitinib in cutaneous disease and efzofitimob in pulmonary disease. Study interpretation is limited by small sample sizes and heterogeneity in study design and population.<\/jats:p>\n                    <jats:p>PROSPERO registration number<\/jats:p>\n                    <jats:p>CRD42024599560<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/thorax-2025-223014","type":"journal-article","created":{"date-parts":[[2025,5,21]],"date-time":"2025-05-21T21:58:11Z","timestamp":1747864691000},"page":"702-710","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":20,"title":["Systematic review and meta-analysis of the efficacy of biologic and targeted synthetic therapies in sarcoidosis"],"prefix":"10.1136","volume":"80","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7552-0463","authenticated-orcid":false,"given":"Katie","family":"Bechman","sequence":"first","affiliation":[{"name":"Centre for Rheumatic Diseases, King\u2019s College London, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathryn","family":"Biddle","sequence":"additional","affiliation":[{"name":"Centre for Rheumatic Diseases, King\u2019s College London, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aitana","family":"Miracle","sequence":"additional","affiliation":[{"name":"Centre for Rheumatic Diseases, King\u2019s College London, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kelly","family":"He","sequence":"additional","affiliation":[{"name":"Centre for Rheumatic Diseases, King\u2019s College London, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Gibson","sequence":"additional","affiliation":[{"name":"Centre for Rheumatic Diseases, King\u2019s College London, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark D","family":"Russell","sequence":"additional","affiliation":[{"name":"Centre for Rheumatic Diseases, King\u2019s College London, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Walsh","sequence":"additional","affiliation":[{"name":"Department of Dermatology, King\u2019s College Hospital NHS Foundation Trust, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Brex","sequence":"additional","affiliation":[{"name":"Department of Neurology, King\u2019s College Hospital NHS Foundation Trust, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amit S","family":"Patel","sequence":"additional","affiliation":[{"name":"Asthma, Allergy and Lung Biology, King\u2019s College London, London, UK"},{"name":"Department of Respiratory Medicine, King\u2019s College Hospital NHS Foundation Trust, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katherine J","family":"Myall","sequence":"additional","affiliation":[{"name":"Asthma, Allergy and Lung Biology, King\u2019s College London, London, UK"},{"name":"Department of Respiratory Medicine, King\u2019s College Hospital NHS Foundation Trust, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sam","family":"Norton","sequence":"additional","affiliation":[{"name":"Department of Psychology, King\u2019s College London, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Surinder S","family":"Birring","sequence":"additional","affiliation":[{"name":"Asthma, Allergy and Lung Biology, King\u2019s College London, London, UK"},{"name":"Department of Respiratory Medicine, King\u2019s College Hospital NHS Foundation Trust, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1230-2781","authenticated-orcid":false,"given":"James","family":"Galloway","sequence":"additional","affiliation":[{"name":"Centre for Rheumatic Diseases, King\u2019s College London, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2025,5,19]]},"reference":[{"key":"2025091502101095000_80.10.702.1","doi-asserted-by":"publisher","DOI":"10.1055\/s-0034-1381229"},{"key":"2025091502101095000_80.10.702.2","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000007595","article-title":"Multidisciplinary approach and long-term follow-up in a series of 640 consecutive patients with sarcoidosis: Cohort study of a 40-year clinical experience at a tertiary referral center in Barcelona, Spain","volume":"96","author":"Ma\u00f1\u00e1","year":"2017","journal-title":"Medicine (Baltimore)"},{"key":"2025091502101095000_80.10.702.3","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.04079-2020","article-title":"ERS clinical practice guidelines on treatment of sarcoidosis","volume":"58","author":"Baughman","year":"2021","journal-title":"Eur Respir J"},{"key":"2025091502101095000_80.10.702.4","doi-asserted-by":"crossref","DOI":"10.1183\/23120541.00597-2021","article-title":"Epidemiology of interstitial lung diseases and their progressive-fibrosing behaviour in six European countries","volume":"8","author":"Hilberg","year":"2022","journal-title":"ERJ Open Res"},{"key":"2025091502101095000_80.10.702.5","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.00002512"},{"key":"2025091502101095000_80.10.702.6","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2020.545413","article-title":"Treatment of Sarcoidosis: A Multidisciplinary Approach","volume":"11","author":"Gerke","year":"2020","journal-title":"Front Immunol"},{"key":"2025091502101095000_80.10.702.7","doi-asserted-by":"publisher","DOI":"10.1136\/thoraxjnl-2019-214348"},{"key":"2025091502101095000_80.10.702.8","doi-asserted-by":"publisher","DOI":"10.1161\/CIR.0000000000001240"},{"key":"2025091502101095000_80.10.702.9","doi-asserted-by":"publisher","DOI":"10.1080\/17512433.2018.1486706"},{"key":"2025091502101095000_80.10.702.10","doi-asserted-by":"publisher","DOI":"10.1001\/jama.287.10.1301"},{"key":"2025091502101095000_80.10.702.11","first-page":"518","article-title":"Methotrexate as a single agent for treating pulmonary sarcoidosis: a single centre real-life prospective study","volume":"82","author":"Goljan-Geremek","year":"2014","journal-title":"Pneumonol Alergol Pol"},{"key":"2025091502101095000_80.10.702.12","first-page":"217","article-title":"Effectiveness and tolerability of methotrexate in pulmonary sarcoidosis: A single center real-world study","volume":"36","author":"Fang","year":"2019","journal-title":"Sarcoidosis Vasc Diffuse Lung Dis"},{"key":"2025091502101095000_80.10.702.13","unstructured":"England N . Clinical Commissioning Policy: Infliximab for refractory sarcoidosis (excluding neurosarcoidosis) (adults) (2204), 2023. Available: https:\/\/www.england.nhs.uk\/wp-content\/uploads\/2023\/11\/2204-ccp-infliximab-upadted.pdf [Accessed 2 Oct 2024]."},{"key":"2025091502101095000_80.10.702.14","doi-asserted-by":"publisher","DOI":"10.1002\/acr.24496"},{"key":"2025091502101095000_80.10.702.15","doi-asserted-by":"publisher","DOI":"10.1016\/j.semarthrit.2018.10.005"},{"key":"2025091502101095000_80.10.702.16","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejim.2022.12.003"},{"key":"2025091502101095000_80.10.702.17","unstructured":"McKenzie JE , Brennan SE . Chapter 12: synthesizing and presenting findings using other methods last updated october 2019. 6. 2024: 5."},{"key":"2025091502101095000_80.10.702.18","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.200603-402OC"},{"key":"2025091502101095000_80.10.702.19","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.00051907"},{"key":"2025091502101095000_80.10.702.20","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.00000914"},{"key":"2025091502101095000_80.10.702.21","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2012.10.056"},{"key":"2025091502101095000_80.10.702.22","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCEP.123.011869","article-title":"Interleukin-1 Blockade in Cardiac Sarcoidosis: A Pilot Study","volume":"16","author":"Kron","year":"2023","journal-title":"Circ Arrhythm Electrophysiol"},{"key":"2025091502101095000_80.10.702.23","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kead373"},{"key":"2025091502101095000_80.10.702.24","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-022-30615-x","article-title":"Inhibition of type 1 immunity with tofacitinib is associated with marked improvement in longstanding sarcoidosis","volume":"13","author":"Damsky","year":"2022","journal-title":"Nat Commun"},{"key":"2025091502101095000_80.10.702.25","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.00227014"},{"key":"2025091502101095000_80.10.702.26","first-page":"201","article-title":"A double-blinded, randomized, placebo-controlled trial of infliximab in subjects with active pulmonary sarcoidosis","volume":"23","author":"Rossman","year":"2006","journal-title":"Sarcoidosis Vasc Diffuse Lung Dis"},{"key":"2025091502101095000_80.10.702.27","first-page":"46","article-title":"Efficacy Results of a 52-week Trial of Adalimumab in the Treatment of Refractory Sarcoidosis","volume":"31","author":"Sweiss","year":"2014","journal-title":"Sarcoidosis Vasc Diffuse Lung Dis"},{"key":"2025091502101095000_80.10.702.28","doi-asserted-by":"publisher","DOI":"10.1378\/chest.128.2.1062"},{"key":"2025091502101095000_80.10.702.29","doi-asserted-by":"publisher","DOI":"10.1378\/chest.124.1.177"},{"key":"2025091502101095000_80.10.702.30","doi-asserted-by":"publisher","DOI":"10.1016\/j.chest.2022.10.037"},{"key":"2025091502101095000_80.10.702.31","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.00224513"},{"key":"2025091502101095000_80.10.702.32","doi-asserted-by":"publisher","DOI":"10.1007\/s00408-021-00436-8"},{"key":"2025091502101095000_80.10.702.33","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaut.2024.103247"},{"key":"2025091502101095000_80.10.702.34","doi-asserted-by":"publisher","DOI":"10.1016\/j.cyto.2016.08.014"},{"key":"2025091502101095000_80.10.702.35","first-page":"829","article-title":"The evidence for biologic immunotherapy in Sarcoidosis: A systematic review","volume":"10","author":"Shah","year":"2017","journal-title":"AMJ"},{"key":"2025091502101095000_80.10.702.36","doi-asserted-by":"publisher","DOI":"10.1016\/j.rmed.2019.01.001"},{"key":"2025091502101095000_80.10.702.37","doi-asserted-by":"publisher","DOI":"10.1513\/AnnalsATS.202006-607OC"}],"container-title":["Thorax"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/thorax-2025-223014","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,15]],"date-time":"2025-09-15T09:10:41Z","timestamp":1757927441000},"score":1,"resource":{"primary":{"URL":"https:\/\/thorax.bmj.com\/lookup\/doi\/10.1136\/thorax-2025-223014"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,19]]},"references-count":37,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2025,9,15]]},"published-print":{"date-parts":[[2025,10]]}},"alternative-id":["10.1136\/thorax-2025-223014"],"URL":"https:\/\/doi.org\/10.1136\/thorax-2025-223014","relation":{},"ISSN":["0040-6376","1468-3296"],"issn-type":[{"value":"0040-6376","type":"print"},{"value":"1468-3296","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,19]]}}}